Literature DB >> 25262263

Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis.

Dimitrios Alexopoulos1, Ioanna Xanthopoulou2, Robert F Storey3, Kevin P Bliden4, Udaya S Tantry4, Dominick J Angiolillo5, Paul A Gurbel4.   

Abstract

BACKGROUND: Factors associated with platelet reactivity (PR) during ticagrelor maintenance dose (MD) are not well defined. We aimed to examine factors that influence levels of PR during chronic ticagrelor therapy.
METHODS: We performed individual participant data meta-analysis of 445 patients from 8 studies who had PR assessment with the VerifyNow P2Y12 assay (Accumetrics, Inc, San Diego, CA) while on ticagrelor 90 mg twice a day MD for at least 14 days.
RESULTS: Distribution of PR during ticagrelor MD was highly skewed toward lower values. No case of high PR (≥230 P2Y12 reaction units [PRU]) was observed. Age and body mass index (BMI) positively affected PR, with every increase in decade and 5 units of BMI resulting in 7.9% and 4.1% increase in PR, respectively. Current smoking status negatively affected PR with 13.7% decrease in PR in current smokers, compared with nonsmokers. Low PR (LPR) was defined as the lowest quartile of PR values (<10 PRU). In multivariate analysis, diabetes mellitus and age >70 years were independently associated with lower probability for LPR with a relative risk (95% CIs) of 0.570 (0.361-0.899) and 0.554 (0.325-0.944), P = .016 and P = .030, respectively.
CONCLUSIONS: Age, BMI, and current smoking status affect PR during ticagrelor MD. Diabetes mellitus and age >70 years were found to be associated with lower probability for LPR. Further research is required to assess the clinical implications of these findings in ticagrelor-treated patients.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25262263     DOI: 10.1016/j.ahj.2014.06.026

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  14 in total

1.  Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.

Authors:  Pegah Ghamasaee; Kevin Carr; Jeremiah Johnson; Ramesh Grandhi
Journal:  Interv Neuroradiol       Date:  2017-04-09       Impact factor: 1.610

2.  Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.

Authors:  Andrew Yang; Quin Pon; Andrea Lavoie; Jennifer J Crawford; Sebastian Harenberg; Rodney H Zimmermann; Jeff Booker; Sheila Kelly; Shahar Lavi; Warren J Cantor; Shamir R Mehta; Akshay Bagai; Shaun G Goodman; Asim N Cheema; Payam Dehghani
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

3.  A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.

Authors:  P C Rath; Sundar Chidambaram; Pallavi Rath; Byomakesh Dikshit; Sudhir Naik; Prashant K Sahoo; Brajraj Das; Mohanshankar Mahalingam; Lakshmipathi Khandrika; Jugnu Jain
Journal:  Indian Heart J       Date:  2015-04-27

4.  Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.

Authors:  Monica Verdoia; Patrizia Pergolini; Matteo Nardin; Roberta Rolla; Francesco Tonon; Elvin Kedhi; Harry Suryapranata; Alessandro Carriero; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2019-10       Impact factor: 2.300

5.  Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.

Authors:  Monica Verdoia; Patrizia Pergolini; Matteo Nardin; Roberta Rolla; Lucia Barbieri; Alon Schaffer; Paolo Marino; Giorgio Bellomo; Harry Suryapranata; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

6.  Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.

Authors:  Christoph B Olivier; Katharina Schnabel; Susanne Weber; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

7.  Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes.

Authors:  Gjin Ndrepepa; Stefan Holdenrieder; Isabell Bernlochner; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2021-12-01       Impact factor: 6.138

8.  Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome.

Authors:  Yuting Zou; Yuyan Wang; Yangxun Wu; Shizhao Zhang; Haiping Liu; Tong Yin
Journal:  Thromb J       Date:  2022-04-21

9.  Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.

Authors:  Dimitrios Alexopoulos; Chrysoula Vogiatzi; Katerina Stavrou; Niki Vlassopoulou; Angelos Perperis; Ioanna Pentara; Ioanna Xanthopoulou
Journal:  Cardiovasc Diabetol       Date:  2015-05-30       Impact factor: 9.951

10.  Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients.

Authors:  Dan-Dan Li; Xu-Yun Wang; Shao-Zhi Xi; Jia Liu; Liu-An Qin; Jing Jing; Tong Yin; Yun-Dai Chen
Journal:  J Geriatr Cardiol       Date:  2016-05       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.